Latest & greatest articles for sofosbuvir

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sofosbuvir or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sofosbuvir and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sofosbuvir

21. [Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - benefit assessment according to õ35a Social Code Book V]

[Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) - benefit assessment according to õ35a Social Code Book V] Sofosbuvir/velpatasvir/ voxilaprevir (chronische hepatitis C): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-35 [Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) – benefit assessment according to §35a Social Code Book V] Sofosbuvir/velpatasvir/ voxilaprevir (chronische hepatitis C): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-35 (...) [Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) – benefit assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Sofosbuvir/velpatasvir/ voxilaprevir (chronische

2018 Health Technology Assessment (HTA) Database.

22. [Ledipasvir/sofosbuvir (hepatitis C) - benefit assessment according to õ35a Social Code Book V]

[Ledipasvir/sofosbuvir (hepatitis C) - benefit assessment according to õ35a Social Code Book V] Ledipasvir/Sofosbuvir (chronische Hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-41 [Ledipasvir/sofosbuvir (hepatitis C) – benefit assessment according to §35a Social Code Book V] Ledipasvir/Sofosbuvir (chronische Hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-41 [Ledipasvir/sofosbuvir (hepatitis C (...) ) – benefit assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ledipasvir/Sofosbuvir (chronische Hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V

2018 Health Technology Assessment (HTA) Database.

23. sofosbuvir velpatasvir voxilaprevir (TBC)

sofosbuvir velpatasvir voxilaprevir (TBC) sofosbuvir velpatasvir voxilaprevir | CADTH.ca Find the information you need sofosbuvir velpatasvir voxilaprevir sofosbuvir velpatasvir voxilaprevir Last Updated: April 4, 2018 Result type: Reports Project Number: SR0529-000 Product Line: Generic Name: sofosbuvir velpatasvir voxilaprevir Brand Name: Vosevi Manufacturer: Gilead Sciences Canada, Inc. Indications: Hepatitis C, chronic Submission Type: New Combination Project Status: Complete Biosimilar (...) recommendation & redacted CDR review report(s) sent to applicant and drug plans January 02, 2018 Embargo period ended and validation of redacted CDR review report(s) received January 16, 2018 CDEC Final Recommendation issued to applicant and drug plans January 23, 2018 CDEC Final Recommendation posted January 25, 2018 Final CDR review report(s) and patient input posted February 07, 2018 Tags hepatitis, hepatitis c, sofosbuvir; velpatasvir; voxilaprevir Files Follow us: © 2019 Canadian Agency for Drugs

2018 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

24. Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) ? Benefit assessment according to §35a Social Code Book V

Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.9 of the dossier assessment Sofosbuvir/Velpatasvir/Voxilaprevir (chronische Hepatitis C) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 November 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. IQWiG Reports – Commission No. A17-35 Sofosbuvir/velpatasvir/ voxilaprevir (chronic hepatitis C) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-35 Version 1.0 Sofosbuvir/velpatasvir/ voxilaprevir (chronic hepatitis C) 13 November 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sofosbuvir/velpatasvir/voxilaprevir (chronic hepatitis C

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

25. Ledipasvir/sofosbuvir (hepatitis C) ? Benefit assessment according to §35a Social Code Book V

Ledipasvir/sofosbuvir (hepatitis C) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Ledipasvir/Sofosbuvir (chronische Hepatitis C bei Jugendlichen) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 November 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG (...) Reports – Commission No. A17-41 Ledipasvir/sofosbuvir (chronic hepatitis C in adolescents) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-41 Version 1.0 Ledipasvir/sofosbuvir (chronic hepatitis C in adolescents) 13 November 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ledipasvir/sofosbuvir (chronic hepatitis C in adolescents) – Benefit

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

26. Sofosbuvir/velpatasvir for hepatitis C virus infection

Sofosbuvir/velpatasvir for hepatitis C virus infection Sofosbuvir/velpatasvir for hepatitis C virus infection - NPS MedicineWise Log In Menu Featured topics Professional development Publications An independent peer-reviewed journal providing critical commentary on drugs and therapeutics. Timely, independent, evidence-based information on new drugs and medical tests, and changes to the PBS and MBS. Featured topics Talk to a professional Information for consumers on prescription, over-the-counter (...) February 2019 4 February 2019 18 October 2018 Featured topic 20 years of helping Australians make better decisions about medicines, medical tests and other health technologies Partner with us Latest projects Search Search Search Search POPULAR Log in Log in All fields are required Email address* Password* Log in Breadcrumb And Text Resize Sofosbuvir/velpatasvir for hepatitis C virus infection Sofosbuvir/velpatasvir for hepatitis C virus infection 4 min read 25 October 2017 A single tablet regimen

2018 National Prescribing Service Limited (Australia)

27. Sofosbuvir induced steven Johnson Syndrome in a patient with hepatitis C virus‐related cirrhosis Full Text available with Trip Pro

Sofosbuvir induced steven Johnson Syndrome in a patient with hepatitis C virus‐related cirrhosis Sofosbuvir is an imperative drug used in treatment regimens for hepatitis C virus (HCV). It is considered relatively safe with fewer adverse effects than other treatments. Here, we report a rare and potentially serious, dermatologic, adverse effect following the use of sofosbuvir. A 35-year-old man with genotype 3-related HCV cirrhosis presented with decompensated ascites and jaundice following 7 (...) weeks of therapy with peginterferon alpha-2a and oral ribavirin. After peginterferon withdrawal and stabilization, oral sofosbuvir and ribavirin were started; 10 days later, he developed itching over the trunk and legs, followed by multiple papules and vesicles over an erythematous base. Over the next 15 days, the rash progressed with the formation of blisters and peeling skin. Simultaneously, the oral mucosa and lips developed crusting and painful erosions. Considering drug-induced Steven John

2017 Hepatology communications

28. Sofosbuvir, velpatasvir, and voxilaprevir (Vosevi) - To treat adults with chronic hepatitis C virus

Sofosbuvir, velpatasvir, and voxilaprevir (Vosevi) - To treat adults with chronic hepatitis C virus Drug Approval Package: VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) Company: Gilead Sciences, Inc. Application No.: 209195Orig1s000 Approval Date: July 18, 2017 Persons with disabilities having problems accessing the PDF files below may call (301

2017 FDA - Drug Approval Package

29. Sofosbuvir/velpatasvir (chronic hepatitis C) - Benefit assessment according to §35a SGB V

Sofosbuvir/velpatasvir (chronic hepatitis C) - Benefit assessment according to §35a SGB V Extract 1 Translation of Sections 2.1 to 2.13 of the dossier assessment Sofosbuvir/Velpatasvir (chronische Hepatitis C) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 October 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission (...) No. A16-48 Sofosbuvir/velpatasvir (chronic hepatitis C) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A16-48 Version 1.0 Sofosbuvir/velpatasvir (chronic hepatitis C) 13 October 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sofosbuvir/velpatasvir (chronic hepatitis C) – Benefit assessment according to §35a Social Code Book V Commissioning agency

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

30. Sofosbuvir/velpatasvir (chronic hepatitis C) - Addendum to Commission A16-48

Sofosbuvir/velpatasvir (chronic hepatitis C) - Addendum to Commission A16-48 1 Translation of addendum A16-73 Sofosbuvir/Velpatasvir (chronische Hepatitis C) – Addendum zum Auftrag A16-48 (Version 1.0; Status: 8 December 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 8 December 2016 1.0 Commission: A16-73 Version: Status: IQWiG Reports (...) – Commission No. A16-73 Sofosbuvir/velpatasvir (chronic hepatitis C) – Addendum to Commission A16-48 1 Addendum A16-73 Version 1.0 Sofosbuvir/velpatasvir – Addendum to Commission A16-48 8 December 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Sofosbuvir/velpatasvir (chronic hepatitis C) – Addendum to Commission A16-48 Commissioning agency: Federal Joint Committee Commission awarded on: 23

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

31. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. Full Text available with Trip Pro

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. Patients who are chronically infected with hepatitis C virus (HCV) and who do not have a sustained virologic response after treatment with regimens containing direct-acting antiviral agents (DAAs) have limited retreatment options.We conducted two phase 3 trials involving patients who had been previously treated with a DAA-containing regimen. In POLARIS-1, patients with HCV genotype 1 infection who had previously (...) received a regimen containing an NS5A inhibitor were randomly assigned in a 1:1 ratio to receive either the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the protease inhibitor voxilaprevir (150 patients) or matching placebo (150 patients) once daily for 12 weeks. Patients who were infected with HCV of other genotypes (114 patients) were enrolled in the sofosbuvir-velpatasvir-voxilaprevir group. In POLARIS-4, patients with HCV genotype 1, 2, or 3 infection who had

2017 NEJM Controlled trial quality: uncertain

32. Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C Full Text available with Trip Pro

Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C Background and Aims: Recurrent infection of hepatitis C virus (HCV) in liver transplant (LT) recipients is universal and associated with significant morbidity and mortality. Methods: We retrospectively evaluated the safety and efficacy of ledipasvir/sofosbuvir with and without ribavirin in LT recipients with recurrent genotype 1 hepatitis C. Results: Eighty-five LT recipients were (...) treated with ribavirin required drug cessation due to side effects, with 4 of those being anemia complications. No recipient discontinued the ledipasvir/sofosbuvir. Eighty-one percent of recipients had undetectable viral levels at 4 weeks after starting therapy, and all recipients had complete viral suppression at the end of therapy. The sustained viral response at 12 weeks after completion of therapy was 94%. Conclusion : Ledipasvir and sofosbuvir with and without ribavirin therapy is an effective

2017 Journal of clinical and translational hepatology

33. Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen Full Text available with Trip Pro

Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen There is paucity of data on sofosubvir (SOF)-based therapy in patients on maintenance hemodialysis (MHD). The objective of this report is to describe our experience using SOF-based direct antiviral agent (DAA) therapy in MHD patients in India.All patients on MHD and treated with SOF-based therapy were included in this study. Before starting treatment, viral load, genotype, liver fibroscan, and upper gastrointestinal

2017 Kidney international reports

34. Sofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center Experience Full Text available with Trip Pro

Sofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center Experience Background and Aims: Patients with chronic hepatitis C (CHC) and end-stage renal disease (ESRD) who are dialysis-dependent form a unique group, in which safety, tolerability and efficacy of sofosbuvir (SOF)-based direct-acting antivirals (DAAs) need further evaluation. Methods: We performed a retrospective analysis of 14 patients with CHC and ESRD on dialysis who received 15 courses of SOF-based therapy. We

2017 Journal of clinical and translational hepatology

35. Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States Full Text available with Trip Pro

Sofosbuvir-based Regimens with Task Shifting Is Cost-effective in Expanding Hepatitis C Treatment Access in the United States Background and Aims: The current paradigm of specialist physician-managed treatment of chronic hepatitis C virus infection (HCV) is inefficient in absorbing the approximately 3 million patients awaiting treatment in the United States. Task shifting-whereby specialist physicians screen patients for treatment eligibility but on-treatment monitoring is devolved to more

2017 Journal of clinical and translational hepatology

36. Sofosbuvir-velpatasvir for chronic HCV infection

Sofosbuvir-velpatasvir for chronic HCV infection Sofosbuvir-velpatasvir for chronic HCV infection Sofosbuvir-velpatasvir for chronic HCV infection HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Sofosbuvir-velpatasvir for chronic HCV infection. Lansdale: HAYES, Inc. Directory Publication. 2016 Authors' objectives Sofosbuvir-velpatasvir (...) (Epclusa) is a "next-generation" once-daily direct-acting antiretroviral (DAA) combination oral regimen for the treatment of all 6 major hepatitis C virus (HCV) genotypes. The fixed-dose combination pill contains 400 mg of sofosbuvir and 100 mg of velpatasvir. Rationale: Sofosbuvir-velpatasvir is intended to treat any genotype and subtype of HCV using an existing drug with accepted efficacy, plus a new drug that is intended to improve efficacy by targeting HCV in a different way. Relevant Questions

2017 Health Technology Assessment (HTA) Database.

37. [Sofosbuvir/velpatasvir (chronic hepatitis C) - benefit assessment according to õ35a SGB V]

[Sofosbuvir/velpatasvir (chronic hepatitis C) - benefit assessment according to õ35a SGB V] Sofosbuvir/celpatasvir (chronische hepatitis C): nutzenbewertung gemäß § 35a SGB V; dossierbewertungen; auftrag A16-48 [Sofosbuvir/velpatasvir (chronic hepatitis C) - benefit assessment according to §35a SGB V] Sofosbuvir/celpatasvir (chronische hepatitis C): nutzenbewertung gemäß § 35a SGB V; dossierbewertungen; auftrag A16-48 [Sofosbuvir/velpatasvir (chronic hepatitis C) - benefit assessment according (...) to §35a SGB V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Sofosbuvir/celpatasvir (chronische hepatitis C): nutzenbewertung gemäß § 35a SGB V; dossierbewertungen; auftrag A16-48. [Sofosbuvir

2017 Health Technology Assessment (HTA) Database.

38. Sofosbuvir?velpatasvir for treating chronic hepatitis C

Sofosbuvir?velpatasvir for treating chronic hepatitis C Sofosbuvir–v Sofosbuvir–velpatasvir for treating elpatasvir for treating chronic hepatitis C chronic hepatitis C T echnology appraisal guidance Published: 25 January 2017 nice.org.uk/guidance/ta430 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 31Contents Contents 1 Recommendations 4 2 The technology 6 3 Evidence 7 4 Committee

2017 National Institute for Health and Clinical Excellence - Technology Appraisals

39. EPCLUSA (sofosbuvir/velpatasvir), fixed combination of direct-acting antivirals

EPCLUSA (sofosbuvir/velpatasvir), fixed combination of direct-acting antivirals Haute Autorité de Santé - EPCLUSA (sofosbuvir/velpatasvir), association fixe d’antiviraux à action directe Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les Médicaments EPCLUSA (sofosbuvir/velpatasvir), association fixe d’antiviraux à action directe Substance active (DCI (...) ) sofosbuvir velpatasvir INFECTIOLOGIE - NOUVEAU MEDICAMENT Nature de la demande Réévaluation SMR et ASMR et Inscription Avis de la CT du 19 octobre 2016 Comme les autres antiviraux d’action directe (HARVONI, DAKLINZA, OLYSIO, VIEKIRAX, EXVIERA), progrès thérapeutique mineur dans le traitement de l’hépatite C chronique de génotypes 1 à 6. EPCLUSA a l’AMM dans le traitement de l’hépatite C chronique chez l’adulte infecté par un virus de l’hépatite C (VHC) de génotypes 1 à 6. Son efficacité virologique

2017 Haute Autorite de sante

40. Adverse effects of pseudoephedrine and sofosbuvir

Adverse effects of pseudoephedrine and sofosbuvir Prescrire IN ENGLISH - Spotlight ''In the January issue of Prescrire International: adverse effects of pseudoephedrine and sofosbuvir'', 1 January 2017 {1} {1} {1} | | > > > In the January issue of Prescrire International: adverse effects of pseudoephedrine and sofosbuvir Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |  (...)  |  Spotlight In the January issue of Prescrire International: adverse effects of pseudoephedrine and sofosbuvir FREE DOWNLOAD In the "Adverse Effects" section of this month's issue, ischaemic colitis with the decongestant pseudoephedrine, and a risk of pulmonary arterial hypertension with the hepatitis C drug sofosbuvir. Full text available for free download. Pseudoephedrine: ischaemic colitis Sympathomimetic vasoconstrictors can provoke neurological and cardiovascular adverse effects

2017 Prescrire